Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.57 |
| ▸ | APP | P05067 | 4/20 | 0.56 |
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298729 | 1.00 | BACE1 (0.57) | BACE1BACE2APPCTSDGAA | |
| SCHEMBL6298730 | 1.00 | BACE1 (0.57) | BACE1BACE2APPCTSDGAA | |
| SCHEMBL8367408 | 0.92 | BACE1 (0.57) | BACE1BACE2APPCTSDGAA | |
| SCHEMBL6295359 | 0.90 | BACE1 (0.59) | BACE1BACE2APPCTSD | |
| SCHEMBL6298866 | 0.88 | BACE1 (0.52) | BACE1BACE2APPCTSD | |
| SCHEMBL6294127 | 0.88 | BACE1 (0.71) | BACE1BACE2APPCTSD | |
| SCHEMBL6294154 | 0.82 | BACE1 (0.66) | BACE1BACE2APPCTSD | |
| SCHEMBL14136382 | 0.82 | BACE1 (0.82) | BACE1BACE2APPCTSD | |
| SCHEMBL13228116 | 0.80 | BACE1 (0.49) | BACE1BACE2APPCTSDKMT2A | |
| SCHEMBL13325771 | 0.80 | BACE1 (0.49) | BACE1BACE2APPCTSDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962934-B2 | Substituted amino carboxamides for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | claimed |
| US-20030166580-A1 | Substituted amino carboxamides for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | claimed |
| US-6962934-B2 | Substituted amino carboxamides for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030166580-A1 | Substituted amino carboxamides for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| WO-2003057721-A2 | SUBSTITUTED AMINO CARBOXAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166580-A1 | Substituted amino carboxamides for the treatment of alzheimer's disease | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885APP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.